[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![ARK_Funds Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1598444521918021632.png) ARK Funds [@ARK_Funds](/creator/twitter/ARK_Funds) on x 17.9K followers
Created: 2025-07-21 20:23:11 UTC

Eli Lilly’s $1.3B acquisition of Verve Therapeutics signals gene editing is ready to scale. Using Beam Therapeutics’ base editing tech, Verve is targeting heart disease. @Shea_ARK shares our $BEAM investment rationale in the Q2 webinar.

Holdings:


XXXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1947391929521738148/c:line.svg)

**Related Topics**
[investment](/topic/investment)
[stocks](/topic/stocks)
[signals](/topic/signals)
[acquisition](/topic/acquisition)
[$13b](/topic/$13b)
[ark](/topic/ark)
[beam beam therapeutics inc](/topic/beam-beam-therapeutics-inc)
[$beam](/topic/$beam)

[Post Link](https://x.com/ARK_Funds/status/1947391929521738148)